Full Text
Polycystic ovary syndrome is a complex endocrine-metabolic disorder affecting a substantial proportion of women during reproductive age and remains one of the leading causes of infertility and hormonal dysfunction worldwide. The syndrome is characterized by chronic anovulation, hyperandrogenism, menstrual irregularity, and polycystic ovarian morphology accompanied by significant metabolic abnormalities. Although the exact etiology remains incompletely understood, development of the syndrome is associated with interactions among genetic predisposition, insulin resistance, endocrine imbalance, chronic inflammation, obesity, environmental influences, and lifestyle-related factors. Hyperinsulinemia and insulin resistance play central pathogenic roles by stimulating ovarian androgen production and disrupting normal follicular maturation. Elevated androgen levels contribute to menstrual dysfunction, acne, hirsutism, ovulatory disorders, and impaired reproductive capacity. Women with polycystic ovary syndrome frequently experience infertility due to chronic anovulation and reduced endometrial receptivity. In addition to reproductive impairment, the syndrome is strongly associated with obesity, dyslipidemia, hypertension, impaired glucose tolerance, metabolic syndrome, and increased risk of type 2 diabetes mellitus and cardiovascular disease. Chronic low-grade inflammation and oxidative stress further contribute to metabolic dysfunction and progression of systemic complications. Psychological manifestations including anxiety, depression, reduced self-esteem, and impaired quality of life are also frequently observed among affected individuals. The heterogeneity of clinical presentation often complicates diagnosis and delays therapeutic intervention. Contemporary management therefore emphasizes comprehensive multidisciplinary evaluation including hormonal, metabolic, reproductive, and psychological assessment to optimize treatment strategies and prevent long-term complications associated with polycystic ovary syndrome. Polycystic ovary syndrome represents a complex multifactorial endocrine-metabolic disorder and remains one of the leading causes of infertility and hormonal dysfunction among women worldwide. The syndrome affects multiple physiological systems and is characterized by chronic anovulation, menstrual disturbance, excessive androgen production, and metabolic abnormalities accompanied by structural ovarian changes. Although exact etiological mechanisms remain incompletely understood, development of the syndrome is associated with interactions between genetic predisposition, insulin resistance, obesity, chronic inflammation, environmental influences, and neuroendocrine dysregulation. Hyperinsulinemia plays a central pathogenic role by stimulating ovarian androgen synthesis and impairing normal follicular maturation, thereby contributing to ovulatory dysfunction and infertility. Elevated androgen levels additionally lead to acne, hirsutism, alopecia, seborrhea, and menstrual irregularities that substantially affect psychological well-being and quality of life. Women with polycystic ovary syndrome frequently exhibit obesity, dyslipidemia, hypertension, impaired glucose tolerance, metabolic syndrome, and increased susceptibility to type 2 diabetes mellitus and cardiovascular disease. Chronic inflammatory activation and oxidative stress further aggravate metabolic dysfunction and endocrine instability. Clinical manifestations often vary considerably among patients, making diagnosis and long-term management particularly challenging. Delayed diagnosis may contribute to progression of reproductive dysfunction, endometrial abnormalities, and chronic systemic metabolic complications. Modern reproductive medicine and endocrinology increasingly emphasize comprehensive multidisciplinary assessment involving gynecological, hormonal, metabolic, cardiovascular, and psychological evaluation to optimize therapeutic strategies and improve long-term health outcomes. Lifestyle modification, hormonal regulation, insulin-sensitizing therapy, and individualized reproductive support currently represent fundamental components of contemporary management approaches in women affected by polycystic ovary syndrome.
2. Materials and Methods
This study was conducted using retrospective and prospective clinical analysis of women diagnosed with polycystic ovary syndrome between 2020 and 2025. Patients included in the study underwent comprehensive gynecological, endocrinological, and metabolic evaluation based on established diagnostic criteria. Clinical assessment included analysis of menstrual history, reproductive function, body mass index, waist circumference, blood pressure, signs of hyperandrogenism, and lifestyle factors. Laboratory investigations included hormonal profile assessment involving luteinizing hormone, follicle-stimulating hormone, testosterone, insulin, glucose, glycated hemoglobin, lipid profile, and inflammatory markers. Pelvic ultrasonography was performed to evaluate ovarian morphology and follicular changes. Insulin resistance was assessed using metabolic indices and glucose tolerance testing where indicated. Patients were stratified according to reproductive dysfunction severity and metabolic abnormalities. Therapeutic management included lifestyle modification, dietary intervention, weight reduction strategies, hormonal therapy, insulin-sensitizing agents, ovulation induction protocols, and psychological support where necessary. Statistical analysis was performed to determine associations between hormonal imbalance, metabolic dysfunction, reproductive impairment, and clinical outcomes.
Clinical evaluation demonstrated that menstrual irregularities, chronic anovulation, infertility, obesity, and insulin resistance were highly prevalent among women with polycystic ovary syndrome. Many patients presented with oligomenorrhea, amenorrhea, acne, hirsutism, and weight gain associated with elevated androgen levels and metabolic disturbances. Laboratory analysis revealed increased insulin concentration, impaired glucose metabolism, dyslipidemia, elevated inflammatory markers, and altered gonadotropin ratios consistent with endocrine dysfunction. Pelvic ultrasonography demonstrated enlarged ovaries with multiple immature follicles and characteristic polycystic morphology in the majority of patients. Women with obesity exhibited significantly greater insulin resistance, inflammatory activity, and reproductive dysfunction compared with individuals of normal body mass index. Infertility and ovulatory dysfunction were strongly associated with hyperinsulinemia and elevated androgen concentration. Lifestyle-oriented interventions including dietary modification, physical activity enhancement, and weight reduction resulted in significant improvement of menstrual regularity, insulin sensitivity, metabolic profile, and ovulatory function during follow-up observation. Pharmacological therapy with insulin-sensitizing agents and hormonal regulation contributed to reduction of hyperandrogenic symptoms and improvement of reproductive outcomes. Patients receiving comprehensive multidisciplinary management demonstrated greater therapeutic effectiveness and improved quality of life compared with individuals receiving isolated symptomatic treatment. Clinical and laboratory evaluation demonstrated high prevalence of reproductive dysfunction, obesity, insulin resistance, and endocrine imbalance among women diagnosed with polycystic ovary syndrome. Menstrual irregularities including oligomenorrhea and amenorrhea were observed in the majority of patients and were frequently associated with chronic anovulation and infertility. Hyperandrogenic manifestations including acne, hirsutism, seborrhea, and androgenic alopecia were strongly associated with elevated androgen concentrations and metabolic abnormalities. Laboratory investigations revealed hyperinsulinemia, impaired glucose metabolism, dyslipidemia, elevated inflammatory markers, and altered gonadotropin ratios reflecting significant endocrine and metabolic dysfunction. Ultrasonographic examination demonstrated enlarged ovaries with multiple immature follicles and characteristic polycystic morphology in most patients. Women with obesity exhibited significantly greater insulin resistance, chronic inflammatory activity, reproductive impairment, and cardiovascular risk factors compared with individuals with lower body mass index. Infertility and ovulatory dysfunction were particularly pronounced among patients with severe hyperinsulinemia and metabolic syndrome. Lifestyle-oriented interventions including caloric restriction, nutritional optimization, physical activity enhancement, and weight reduction resulted in improvement of menstrual regularity, ovulatory function, insulin sensitivity, and metabolic parameters during follow-up observation. Pharmacological treatment with insulin-sensitizing agents and hormonal therapy additionally contributed to reduction of hyperandrogenic symptoms and restoration of reproductive function. Patients receiving comprehensive multidisciplinary management demonstrated significantly improved clinical outcomes and quality of life compared with individuals receiving isolated symptomatic treatment.
The findings confirm that polycystic ovary syndrome represents a multifactorial endocrine and metabolic disorder with substantial impact on reproductive and systemic health in women. The syndrome is characterized by complex interactions between hormonal imbalance, insulin resistance, chronic inflammation, obesity, and ovarian dysfunction resulting in significant reproductive and metabolic complications. Hyperinsulinemia plays a critical pathogenic role by stimulating ovarian androgen production and impairing follicular maturation, thereby contributing to chronic anovulation and infertility. Excess androgen levels additionally influence metabolic homeostasis and contribute to development of obesity, dyslipidemia, impaired glucose tolerance, and cardiovascular risk factors. The study demonstrates that women with polycystic ovary syndrome frequently experience coexistence of reproductive impairment and metabolic dysfunction, emphasizing the importance of integrated clinical management. Obesity substantially aggravates endocrine imbalance and inflammatory activity, accelerating progression of metabolic syndrome and insulin resistance. Early identification of metabolic abnormalities is therefore essential for prevention of long-term complications including type 2 diabetes mellitus and cardiovascular disease. Lifestyle modification remains the cornerstone of treatment and includes nutritional optimization, weight reduction, physical activity, and long-term metabolic stabilization. Pharmacological interventions targeting insulin resistance and hormonal imbalance further improve reproductive function and endocrine regulation. Contemporary management increasingly relies on multidisciplinary cooperation among gynecologists, endocrinologists, nutritionists, reproductive specialists, psychologists, and rehabilitation professionals to optimize therapeutic outcomes and improve quality of life in women affected by polycystic ovary syndrome. The findings confirm that polycystic ovary syndrome is a multifaceted endocrine and metabolic disorder exerting profound influence on reproductive health and systemic metabolic regulation in women. The syndrome is characterized by complex interactions between insulin resistance, hormonal imbalance, chronic inflammation, obesity, and ovarian dysfunction resulting in substantial reproductive and metabolic complications. Hyperinsulinemia remains one of the most important pathogenic mechanisms because excessive insulin activity stimulates ovarian androgen production and disrupts physiological follicular development, thereby contributing to chronic anovulation and infertility. Elevated androgen levels additionally influence adipose tissue metabolism, inflammatory pathways, and cardiovascular regulation, accelerating progression of obesity and metabolic syndrome. The study demonstrates that women affected by polycystic ovary syndrome frequently exhibit coexistence of reproductive dysfunction and systemic metabolic abnormalities, emphasizing the importance of integrated therapeutic management. Obesity substantially aggravates endocrine imbalance and inflammatory activation, increasing susceptibility to impaired glucose tolerance, dyslipidemia, hypertension, and long-term cardiovascular complications. Chronic low-grade inflammation and oxidative stress may further contribute to endothelial dysfunction and progression of metabolic disturbances. Early identification of endocrine and metabolic abnormalities therefore remains essential for prevention of long-term complications and preservation of reproductive potential. Lifestyle modification focused on nutritional correction, weight management, and physical activity remains the cornerstone of treatment and significantly improves insulin sensitivity and hormonal regulation. Pharmacological therapy targeting insulin resistance and hyperandrogenism further enhances reproductive outcomes and metabolic stability. Contemporary management increasingly depends on multidisciplinary cooperation among gynecologists, endocrinologists, nutrition specialists, reproductive physicians, psychologists, and rehabilitation professionals to optimize individualized treatment strategies and improve overall quality of life in women with polycystic ovary syndrome.
Polycystic ovary syndrome is a significant endocrine-metabolic disorder with major impact on reproductive and metabolic health in women. The syndrome is strongly associated with infertility, menstrual dysfunction, obesity, insulin resistance, dyslipidemia, and increased cardiovascular risk. Hormonal imbalance and chronic metabolic dysregulation play central roles in progression of reproductive impairment and systemic complications. Early diagnosis and comprehensive multidisciplinary management involving lifestyle modification, hormonal therapy, metabolic correction, and reproductive support significantly improve clinical outcomes and quality of life. Long-term monitoring and individualized therapeutic strategies remain essential for prevention of endocrine, metabolic, and cardiovascular complications associated with polycystic ovary syndrome. Polycystic ovary syndrome is a significant endocrine-metabolic disorder associated with major reproductive and systemic health consequences in women. The syndrome contributes substantially to infertility, menstrual dysfunction, obesity, insulin resistance, dyslipidemia, and increased cardiovascular risk through complex interactions between hormonal imbalance and metabolic dysregulation. Early diagnosis and comprehensive multidisciplinary management involving lifestyle modification, metabolic stabilization, hormonal therapy, and reproductive support significantly improve clinical outcomes and reduce risk of long-term complications. Individualized therapeutic strategies and continuous monitoring remain essential for preservation of reproductive function, improvement of metabolic health, and enhancement of quality of life in women affected by polycystic ovary syndrome.
[1] Azziz R, Carmina E, Chen Z, et al. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;2:16057.
[2] Teede HJ, Misso ML, Costello MF, et al. International evidence-based guideline for the assessment and management of polycystic ovary syndrome 2023. Hum Reprod. 2023;38(9):1607–1640.
[3] Rosenfield RL, Ehrmann DA. The pathogenesis of polycystic ovary syndrome. J Clin Endocrinol Metab. 2016;101(11):3720–3730.
[4] Escobar-Morreale HF. Polycystic ovary syndrome: definition, aetiology, diagnosis and treatment. Nat Rev Endocrinol. 2018;14(5):270–284.
[5] Dumesic DA, Oberfield SE, Stener-Victorin E, et al. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of PCOS. Endocr Rev. 2015;36(5):487–525.
[6] Lizneva D, Suturina L, Walker W, et al. Criteria, prevalence, and phenotypes of polycystic ovary syndrome. Fertil Steril. 2016;106(1):6–15.
[7] Goodarzi MO, Dumesic DA, Chazenbalk G, Azziz R. Polycystic ovary syndrome: etiology, pathogenesis and diagnosis. Nat Rev Endocrinol. 2011;7(4):219–231.
[8] Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance and type 2 diabetes in PCOS. Hum Reprod Update. 2010;16(4):347–363.
[9] Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of PCOS. Fertil Steril. 2012;97(1):28–38.
[10] Legro RS, Arslanian SA, Ehrmann DA, et al. Diagnosis and treatment of PCOS. J Clin Endocrinol Metab. 2013;98(12):4565–4592.
[11] Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited. Endocr Rev. 2012;33(6):981–1030.
[12] Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised diagnostic criteria and long-term health risks related to PCOS. Fertil Steril. 2004;81(1):19–25.
[13] Wild RA, Carmina E, Diamanti-Kandarakis E, et al. Assessment of cardiovascular risk in women with PCOS. Fertil Steril. 2010;94(1):35–43.
[14] Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with PCOS. Hum Reprod Update. 2012;18(6):618–637.
[15] Delitala AP, Capobianco G, Delitala G, Cherchi PL, Dessole S. Polycystic ovary syndrome, adipose tissue and metabolic syndrome. Arch Gynecol Obstet. 2017;296(3):405–419.
[16] March WA, Moore VM, Willson KJ, et al. The prevalence of PCOS in a community sample. Hum Reprod. 2010;25(2):544–551.
[17] World Health Organization. Infertility fact sheet. Geneva: WHO; 2025.
[18] American College of Obstetricians and Gynecologists. Polycystic ovary syndrome. Practice Bulletin. Obstet Gynecol. 2024;143(2):e1–e24.
[19] Med1.uz. Polikistik tuxumdon sindromi haqida umumiy ma’lumot. Available from: https://med1.uz/articles/ginekologiya/pkos
[20] Med1.uz. Ayollarda gormonal buzilishlar va reproduktiv salomatlik. Available from: https://med1.uz/articles/endokrinologiya/gormonal-buzilish
[21] Med1.uz. Polikistik tuxumdon sindromida metabolik o‘zgarishlar. Available from: https://med1.uz/articles/endokrinologiya/metabolik-ozgarishlar
[22] Med1.uz. Ayollar bepushtligining endokrin sabablari. Available from: https://med1.uz/articles/ginekologiya/bepushtlik
[23] Med1.uz. Insulinrezistentlik va PCOS o‘rtasidagi bog‘liqlik. Available from: https://med1.uz/articles/endokrinologiya/insulinrezistentlik
[24] Med1.uz. Ginekologiyada zamonaviy diagnostika usullari. Available from: https://med1.uz/articles/ginekologiya/diagnostika
[25] Med1.uz. Reproduktiv yoshdagi ayollarda semizlik muammosi. Available from: https://med1.uz/articles/diyetologiya/semizlik
[26] Med1.uz. PCOSni kompleks davolash yondashuvlari. Available from: https://med1.uz/articles/ginekologiya/davolash